



## FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

DAVID L. PARKER  
PARTNER  
DPARKER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3055  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

November 29, 2004

### CERTIFICATE OF MAILING 37 C.F.R. 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

November 29, 2004

Date

David L. Parker

### MS AMENDMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/824,627 entitled "METHODS FOR EX VIVO HYBRIDOMA-FREE PRODUCTION OF POLYCLONAL AND MONOCLONAL ANTIBODIES AND GENERATION OF IMMORTALIZED CELL POPULATIONS" – Renata Pasqualini and Wadih Arap*  
*Our reference: UTSC:858US*  
*Client reference: MDA03-071*

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references A1-A18 and C1-C9.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:858US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

David L. Parker  
Reg. No. 32,165

DLP/kmv  
Encl.: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Renata Pasqualini  
Wadih Arap

Serial No.: 10/824,627

Filed: April 14, 2004

For: METHODS FOR EX VIVO  
HYBRIDOMA-FREE PRODUCTION OF  
POLYCLONAL AND MONOCLONAL  
ANTIBODIES AND GENERATION OF  
IMMORTALIZED CELL POPULATIONS

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: UTSC:858US

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

November 29, 2004

Date

David L. Parker

**INFORMATION DISCLOSURE STATEMENT**

**MS AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:858US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



David L. Parker  
Reg. No. 32,165  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: November 29, 2004

Form PTO-1449 (modified)

Atty. Docket No.

UTSC:858US

Serial No.

10/824,627

List of Patents and Publications for Applicant's

Applicant

Renata Pasqualini

Wadih Arap

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

April 14, 2004

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 2

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,270,191	12/14/93	McKay <i>et al.</i>	435	172.3	5/12/92
	A2	5,622,699	4/22/97	Ruoslahti and Pasqualini	424	93.6	9/11/95
	A3	5,658,570	8/19/97	Newman <i>et al.</i>	424	184.1	1/25/95
	A4	5,688,692	11/18/97	Jat <i>et al.</i>	435	354	2/11/93
	A5	5,866,759	2/02/99	Jat <i>et al.</i>	800	2	7/02/97
	A6	5,939,598	8/17/99	Kucherlapati and Jakobovits	800	25	7/30/92
	A7	6,075,181	6/13/00	Kucherlapati <i>et al.</i>	800	25	6/07/95
	A8	6,114,598	9/05/00	Kucherlapati <i>et al.</i>	800	18	6/05/95
	A9	6,150,584	11/21/00	Kucherlapati <i>et al.</i>	800	18	10/02/96
	A10	6,162,963	12/19/00	Kucherlapati <i>et al.</i>	800	18	6/05/95
	A11	6,165,745	12/26/00	Ward and Kim	435	69.1	11/17/94
	A12	6,174,687	1/16/01	Rajotte <i>et al.</i>	435	7.1	2/26/99
	A13	6,232,287	5/15/01	Ruoslahti <i>et al.</i>	514	2	3/13/98
	A14	6,235,883	5/22/01	Jakobovits <i>et al.</i>	530	388.22	5/05/97
	A15	6,399,384	6/04/02	Jat	435	456	9/15/00
	A16	6,602,503	8/05/03	Lobb <i>et al.</i>	424	154.1	5/31/95
	A17	6,657,103	12/02/03	Kucherlapati <i>et al.</i>	800	6	9/04/97
	A18	6,673,986	1/06/04	Kucherlapati <i>et al.</i>	800	18	5/15/93

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No


25419864.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:858US	Serial No. 10/824,627
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Renata Pasqualini Wadih Arap	
		Filing Date: April 14, 2004	Group: 1645
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 2	



### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Breitling and Dubel, <i>Recombinant Antibodies</i> , Wiley Publishers, 1999.
	C2	Daniell, "Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants," <i>Trends Plant Sci.</i> , 6:219-226, 2001.
	C3	Harlow and Lane, In: <i>Antibodies: A Laboratory Manual</i> , Cold Spring Harbor Lab., Cold Spring Harbor, NY, 1988.
	C4	Jat <i>et al.</i> , "Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse," <i>Proc. Natl. Acad. Sci., USA</i> , 88:5096-5100, 1991.
	C5	Karpas <i>et al.</i> , "A human myeloma cell line suitable for the generation of human monoclonal antibodies," <i>Proc. Natl. Acad. Sci., USA</i> , 98:1799-1804, 2001.
	C6	Mintz <i>et al.</i> , "Fingerprinting the circulating repertoire of antibodies from cancer patients," <i>Nat. Biotechnol.</i> , 21(1)L:57-63, 2003.
	C7	Weigel <i>et al.</i> , "Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses," <i>Blood</i> , 100:4169-4176, 2002.
	C8	Winter and Milstein, "Man-made antibodies," <i>Nature</i> , 349:293-299, 1991.
	C9	Winter <i>et al.</i> , "Making antibodies by phage display technology," <i>Annu. Rev. Immunol.</i> , 12:433-455, 1994.

25419864.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.